Top

Published in:

01-10-2015 | Review

B-type natriuretic peptide as a parameter for pulmonary hypertension in children. A systematic review

Authors: Chantal A. ten Kate, Dick Tibboel, Ulrike S. Kraemer

Published in: European Journal of Pediatrics | Issue 10/2015

Abstract

Pulmonary hypertension (PH) is a life-threatening disease with a high mortality rate and a broad variety of underlying etiologies. The current golden standard for diagnosing PH and monitoring efficiency of treatment is right heart catheterization. As an alternative, serum biomarkers have been suggested. Cardiac troponin T (TnT), brain natriuretic peptide (BNP), and NT-proBNP seem the most potential. The aim of this systematic review was to evaluate the current literature on the prognostic value of these biomarkers in children with PH and their usefulness as a diagnostic tool. A systematic literature search yielded 14 studies on patients ≤18 years with proven PH with (NT-pro)BNP or TnT as primary outcome. TnT is suggested to be a promising biomarker, but its usefulness in clinical practice has not been proven. The levels of (NT-pro)BNP seemed to be reliable within one PH category, but differed significantly between categories. NT-proBNP showed a good correlation with mortality and might have a prognostic value.

Conclusion: The lack of absolute levels makes (NT-pro)BNP unsuitable as a diagnostic marker, but in view of the relative changes, it could be used to monitor patients. Further investigation should explore differences in normal (NT-pro)BNP levels between the different categories of PH.

What is known:

• Pulmonary hypertension is a life-threatening disease. Diagnosis can be challenging in children; the current diagnostic options—right heart catheterization and echocardiography—are invasive and/or investigator-dependent procedures.

• Biomarkers could be useful in this context because they are investigator independent and easy to obtain through blood samples. Brain natriuretic peptide (BNP) and its N-terminal cleavage product (NT-proBNP) seem to be the most promising. The value of these biomarkers in the diagnostic approach of PH has already been investigated in adults, with promising results. Pediatric studies are still scarce.

What is new:

• The levels of BNP and NT-proBNP in pediatric patients differ strongly between the different categories of PH. Within the same category, the levels are more or less equal.

• The relative changes could render them a prognostic marker in the follow-up of a certain individual patient. At this moment there is not enough evidence to rely on BNP or NT-proBNP in clinical treatment of patients with PH.

Baptista MJ, Rocha G, Clemente F, Azevedo LF, Tibboel D, Leite-Moreira AF, Guimaraes H, Areias JC, Correia-Pinto J (2008) N-terminal-pro-B type natriuretic peptide as a useful tool to evaluate pulmonary hypertension and cardiac function in CDH infants. Neonatology 94:22–30CrossRefPubMed

Bernus A, Wagner BD, Accurso F, Doran A, Kaess H, Ivy DD (2009) Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. Chest 135:745–751PubMedCentralCrossRefPubMed

Bettencourt PM (2005) Clinical usefulness of B-type natriuretic peptide measurement: present and future perspectives. Heart 91:1489–1494. doi:10.1136/hrt.2005.063784 PubMedCentralCrossRefPubMed

Chida A, Sato H, Shintani M, Nakayama T, Kawamura Y, Furutani Y, Inai K, Saji T, Matsuoka R, Nonoyama S, Nakanishi T (2014) Soluble ST2 and N-terminal pro-brain natriuretic peptide combination: useful biomarker for predicting outcome of childhood pulmonary arterial hypertension. Circ J 78:436–442CrossRefPubMed

Cracowski JL, Leuchte HH (2012) The potential of biomarkers in pulmonary arterial hypertension. Am J Cardiol 110:32S–38S. doi:10.1016/j.amjcard.2012.06.014 CrossRefPubMed

Cuna A, Kandasamy J, Fineberg N (2013) B-type natriuretic peptide is a biomarker for pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Res Rep Neonatol 3:33–36

Cuna A, Kandasamy J, Sims B (2014) B-type natriuretic peptide and mortality in extremely low birth weight infants with pulmonary hypertension: a retrospective cohort analysis. BMC Pediatr 14:68. doi:10.1186/1471-2431-14-68 PubMedCentralCrossRefPubMed

Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, Guidelines ESCCfP (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30:2493–2537CrossRefPubMed

Jan SL, Fu YC, Hwang B, Lin SJ (2012) B-type natriuretic peptide in children with atrial or ventricular septal defect: a cardiac catheterization study. Biomarkers 17:166–171. doi:10.3109/1354750X.2011.649494 CrossRefPubMed

10.

Koch A, Singer H (2003) Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart 89:875–878PubMedCentralCrossRefPubMed

11.

Konduri GG, Kim UO (2009) Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatr Clin North Am 56:579–600. doi:10.1016/j.pcl.2009.04.004 PubMedCentralCrossRefPubMed

12.

Lammers AE, Hislop AA, Haworth SG (2009) Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. Int J Cardiol 135:21–26CrossRefPubMed

13.

Levin ER, Gardner DG, Samson WK (1998) Natriuretic peptides. N Engl J Med 339:321–328. doi:10.1056/NEJM199807303390507 CrossRefPubMed

14.

McLaughlin VV, McGoon MD (2006) Pulmonary arterial hypertension. Circulation 114:1417–1431. doi:10.1161/CIRCULATIONAHA.104.503540 CrossRefPubMed

15.

Nir A, Lindinger A, Rauh M, Bar-Oz B, Laer S, Schwachtgen L, Koch A, Falkenberg J, Mir TS (2009) NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 30:3–8. doi:10.1007/s00246-008-9258-4 CrossRefPubMed

16.

Ozhan H, Albayrak S, Uzun H, Ordu S, Kaya A, Yazici M (2007) Correlation of plasma B-type natriuretic peptide with shunt severity in patients with atrial or ventricular septal defect. Pediatr Cardiol 28:272–275. doi:10.1007/s00246-006-0014-3 CrossRefPubMed

17.

Partridge EA, Hanna BD, Rintoul NE, Herkert L, Flake AW, Adzick NS, Hedrick HL, Peranteau WH (2015) Brain-type natriuretic peptide levels correlate with pulmonary hypertension and requirement for extracorporeal membrane oxygenation in congenital diaphragmatic hernia. J Pediatr Surg 50:263–266. doi:10.1016/j.jpedsurg.2014.11.009 CrossRefPubMed

18.

Ploegstra MJ, Douwes JM, Roofthooft MT, Zijlstra WM, Hillege HL, Berger RM (2014) Identification of treatment goals in paediatric pulmonary arterial hypertension. Eur Respir J 44:1616–1626. doi:10.1183/09031936.00030414 CrossRefPubMed

19.

Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, Biedert S, Schaub N, Buerge C, Potocki M, Noveanu M, Breidthardt T, Twerenbold R, Winkler K, Bingisser R, Mueller C (2009) Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 361:858–867. doi:10.1056/NEJMoa0900428 CrossRefPubMed

20.

Reynolds EW, Ellington JG, Vranicar M, Bada HS (2004) Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics 114:1297–1304CrossRefPubMed

21.

Rosenzweig EB, Feinstein JA, Humpl T, Ivy DD (2009) Pulmonary arterial hypertension in children: diagnostic work-up and challenges. Prog Pediatr Cardiol 27:4–11. doi:10.1016/j.ppedcard.2009.09.003 PubMedCentralCrossRefPubMed

22.

Roy AK, McCullagh BN, Segurado R, McGorrian C, Keane E, Keaney J, Fitzgibbon MN, Mahon NG, Murray PT, Gaine SP (2014) Detection of high-sensitivity troponin in outpatients with stable pulmonary hypertension identifies a subgroup at higher risk of adverse outcomes. J Card Fail 20:31–37. doi:10.1016/j.cardfail.2013.12.001 CrossRefPubMed

23.

Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R (2013) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62:D34–D41. doi:10.1016/j.jacc.2013.10.029 CrossRefPubMed

24.

Stenmark KR, Abman SH (2005) Lung vascular development: implications for the pathogenesis of bronchopulmonary dysplasia. Annu Rev Physiol 67:623–661. doi:10.1146/annurev.physiol.67.040403.102229 CrossRefPubMed

25.

Steurer MA, Moon-Grady AJ, Fineman JR, Sun CE, Lusk LA, Wai KC, Keller RL (2014) B-type natriuretic peptide: prognostic marker in congenital diaphragmatic hernia. Pediatr Res 76:549–554. doi:10.1038/pr.2014.136 PubMedCentralCrossRefPubMed

26.

Suda K, Matsumura M, Matsumoto M (2003) Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 45:249–254CrossRefPubMed

27.

Swaminathan AC, Dusek AC, McMahon TJ (2015) Treatment-related biomarkers in pulmonary hypertension. Am J Respir Cell Mol Biol. doi:10.1165/rcmb.2014-0438TR PubMed

28.

Takatsuki S, Wagner BD, Ivy DD (2012) B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension. Congenit Heart Dis 7:259–267PubMedCentralCrossRefPubMed

29.

Toyono M, Harada K, Tamura M, Aoki-Okazaki M, Shimada S, Oyamada J, Takada G (2008) Paradoxical relationship between B-type natriuretic peptide and pulmonary vascular resistance in patients with ventricular septal defect and concomitant severe pulmonary hypertension. Pediatr Cardiol 29:65–69CrossRefPubMed

30.

van Albada ME, Loot FG, Fokkema R, Roofthooft MTR, Berger RMF (2008) Biological serum markers in the management of pediatric pulmonary arterial hypertension. Pediatr Res 63:321–327CrossRefPubMed

31.

van Loon RL, Roofthooft MT, Hillege HL, ten Harkel AD, van Osch-Gevers M, Delhaas T, Kapusta L, Strengers JL, Rammeloo L, Clur SA, Mulder BJ, Berger RM (2011) Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation 124:1755–1764. doi:10.1161/CIRCULATIONAHA.110.969584 CrossRefPubMed

32.

Vijlbrief DC, Benders MJNL, Kemperman H, Van Bel F, De Vries WB (2012) B-type natriuretic peptide and rebound during treatment for persistent pulmonary hypertension. J Pediatr 160:111–115.e111CrossRefPubMed

Title: B-type natriuretic peptide as a parameter for pulmonary hypertension in children. A systematic review
Authors: Chantal A. ten Kate
Dick Tibboel
Ulrike S. Kraemer
Publication date: 01-10-2015
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Pediatrics / Issue 10/2015
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-015-2619-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

B-type natriuretic peptide as a parameter for pulmonary hypertension in children. A systematic review

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2015

Subjective need for psychological support (PsySupp) in parents of children and adolescents with disorders of sex development (dsd)

Inherited metabolic disorders presenting as acute liver failure in newborns and young children: King’s College Hospital experience

Prevalence and correlates of use of complementary and alternative medicine in children with autism spectrum disorder in Europe

Assessment of parental awareness of the shaken baby syndrome in Ireland

Comparison of the TruView PCD video laryngoscope and macintosh laryngoscope for pediatric tracheal intubation by novice paramedics: a randomized crossover simulation trial

Analysis of medication prescribing errors in critically ill children